Philippe JEAN-PIERRE

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 17/10/2023
• Auteurs : Pierre CharbonnierPhilippe FoucherRaphaël AntoineDiego NavarroBrice Marc
• Organismes : Evaluation non destructive des structures et des matériaux Evaluation non destructive des structures et des matériaux Evaluation non destructive des structures et des matériaux Intelligence artificielle et algorithmes efficaces pour la robotique autonome Evaluation non destructive des structures et des matériaux Evaluation non destructive des structures et des matériaux Modèles statistiques bayésiens et des valeurs extrêmes pour données structurées et de grande dimension

---

Résumé : Chaque année, le Colloque Le Pont réunit les acteurs et les spécialistes du secteur du Génie Civil afin d'aborder ensemble les problématiques de la maintenance des ouvrages d'art à l'occasion de conférences sur des thématiques précises, d'expositions professionnelles et d'échanges. En 2024, la thématique était "L’innovation au service du Génie Civil". Cet exposé tutoriel introduisait la séquence "Le programme Ponts Connectés pour la surveillance et la maintenance des ouvrages" au cours de laquelle six projets du programme Ponts Connectés (2021-2023), piloté par le Cerema dans le cadre du programme gouvernemental France Relance, ont été présentés. Nous y avons proposé une introduction aux principales techniques de vision par ordinateur permettant de réaliser la localisation des appareils de prise de vue et la reconstruction 3D des structures imagées. Nous avons également présenté les méthodes de reconnaissance des formes et leur application à la détection d'anomalies sur ouvrages d'art. Ces notions ont été illustrées par des résultats obtenus par l'équipe de recherche ENDSUM du Cerema, notamment dans le projet ROAD-AI, en collaboration avec l'Inria. Enfin, une description du programme Ponts Connectés a été proposée.

---

Fichiers liés : CharbonnierLePont2023.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 16/10/2023
• Auteurs : Mathieu ChappuyPhilippe LackBaptiste DavidGilles PenavayreDamien ThaboureyMaira LandulphoAnthony PlasseChristophe IcardFrançois BaillyFaroudja BoutahraPierre PradatMarianne MaynardMarie Jauffret-RoustideJulia de TernayBenjamin Rolland
• Organismes : Centre Hospitalier le Vinatier [Bron] Hospices Civils de Lyon Centre de soins, d'accompagnement et de prévention en addictologie [Hôpital de la Croix-Rousse, HCL] Hôpital de la Croix-Rousse [CHU - HCL] Contrôle Artificiel de Mouvements et de Neuroprothèses Intuitives Hôpital de la Croix-Rousse [CHU - HCL] Hôpital de la Croix-Rousse [CHU - HCL] Centre d'étude des mouvements sociaux British Columbia Baldy Center for Law and Social Policy Research on Healthcare Performance Hospices Civils de Lyon Service Universitaire d’Addictologie de Lyon [CH Le Vinatier, Bron] Psychiatric Disorders, Neuroscience Research and Clinical Research
• Publié dans Harm Reduction Journal le 29/10/2020

---

Résumé : Abstract Background Drug consumption rooms (DCRs) have been developed in cities with open drug scenes, with the aim to reduce drug-related harm. In Lyon, France's second-largest city, there is no distinct drug use area, which raised doubts regarding the need for a DCR. Methods We conducted a face-to-face survey of 264 people who use drugs (PWUDs), recruited in harm reduction or addiction treatment centers, in the streets or in squats. We assess their willingness to use a DCR, and we collected sociodemographic and medical features. Bivariable comparisons and analyses adjusted for sociodemographic parameters explored the association between willing to use a DCR and other variables, thus providing crude (ORs) and adjusted odds ratios (aORs) and 95% confidence intervals (95% CI). Results In total, 193 (73.1%) PWUDs accepted to participate (mean age 38.5 ± 9.3 years; 80.3% men). Among them, 64.2% declared willing to use a DCR. Being treatment-seeker (aOR 0.20, 95% CI [0.08–0.51]; p < 0.001) and not living alone (aOR 0.29; 95% CI [0.10–0.86], p = 0.025) were negatively associated with willing to use a DCR. By contrast, receiving precarity social insurance (aOR 4.12; 95% CI [1.86–9.14], p < 0.001), being seropositive for hepatitis C (aOR 3.60; 95% CI [1.20–10.84], p = 0.022), being cannabis user (aOR 2.45; 95% CI [1.01–5.99], p = 0.049), and reporting previous problems with residents (aOR 5.99; 95% CI [2.16–16.58], p < 0.001) or with the police (aOR = 4.85; 95% CI [1.43–16.39], p = 0.011) were positively associated. Conclusions PWUDs, especially the most precarious ones, largely supported the opening of a DCR in Lyon, a city with no open drug scene.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 13/10/2023
• Auteurs : Thiébaud PicartJohan PalludJulien BerthillerChloé DumotMoncef BerhoumaFrancois DucrayXavier ArmoiryJennifer MargierPascale GuerrePascale VarletDavid MeyronetPhilippe MetellusJacques GuyotatElsa MagroPhilippe MeneiHugues LoiseauHenri DufourNicolas ReynsMichel LonjonEdouard GimbertEvelyne EmeryWalid FarahFrançois VassalPierre Jean Le ResteIlyes ZemmouraLuc BauchetOlivier LangloisFabrice ParkerEmmanuel MandonnetFaillot ThierryRémy GuillevinLuc TaillandierAnne TermozNathalie PerretonEstelle Bravant
• Organismes : Hospices Civils de Lyon
• Publié dans Journal of Neurosurgery le 26/10/2020

---

Résumé : OBJECTIVE Only one phase III prospective randomized study, published in 2006, has assessed the performance of 5-aminolevulinic acid (5-ALA) fluorescence-guided surgery (FGS) for glioblastoma resection. The aim of the RESECT study was to compare the onco-functional results associated with 5-ALA fluorescence and with white-light conventional microsurgery in patients with glioblastoma managed according to the current standards of care. METHODS This was a phase III prospective randomized single-blinded study, involving 21 French neurosurgical centers, comparing 5-ALA FGS with white-light conventional microsurgery in patients with glioblastoma managed according to the current standards of care, including neuronavigation use and postoperative radiochemotherapy. Randomization was performed in a 1:1 ratio stratified by institution. 5-ALA (20 mg/kg) or placebo (ascorbic acid) was administered orally 3-5 hours before the incision. The primary endpoint was the rate of gross-total resection (GTR) blindly assessed by an independent committee. Patients without a confirmed pathological diagnosis of glioblastoma or with unavailable postoperative MRI studies were excluded from the per-protocol analysis. RESULTS Between March 2013 and August 2016, a total of 171 patients were assigned to the 5-ALA fluorescence group (n = 88) or to the placebo group (n = 83). Twenty-four cases were excluded because the WHO histological criteria of grade 4 glioma were not met. The proportion of GTR was significantly higher in the 5-ALA fluorescence group (53/67, 79.1%) than in the placebo group (33/69, 47.8%; p = 0.0002). After adjustment for age, preoperative Karnofsky Performance Scale score, and tumor location, GTR was still associated with 5-ALA fluorescence (OR 4.13 [95% CI 1.94-8.79]). The mean 7-day postoperative Karnofsky Performance Scale score (≥ 80% in 49/71, 69.0% [5-ALA group]; 50/71, 70.4% [placebo group], p = 0.86) and the proportion of patients with a worsened neurological status 3 months postoperatively (9/68, 13.2% [5-ALA group]; 9/70, 12.9% [placebo group], p = 0.95) were similar between groups. Adverse events related to 5-ALA intake were rare and consisted of photosensitization in 4/87 (4.6%) patients and hepatic cytolysis in 1/87 (1.1%) patients. The 6-month PFS (70.2% [95% CI 57.7%-79.6%] and 68.4% [95% CI 55.7%-78.1%]; p = 0.39) and 24-month OS (30.1% [95% CI 18.9%-42.0%] and 37.7% [95% CI 25.8%-49.5%]; p = 0.89) did not significantly differ. In multivariate analysis, GTR was an independent predictor of PFS (hazard ratio 0.56 [95% CI 0.36-0.86], p =

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 13/10/2023
• Auteurs : Jérémie DamayTobias BenderChristoph MunkMichael JousserandMilena CretonEmmanuel FredonRomain RémondPierre Jean MeausooneAlexander PfriemPhilippe Gerardin
• Organismes : Laboratoire d'Etudes et de Recherche sur le Matériau Bois Eberswalde University for Sustainable Development Eberswalde University for Sustainable Development Buffet Crampon Buffet Crampon Laboratoire d'Etudes et de Recherche sur le Matériau Bois Laboratoire d'Etudes et de Recherche sur le Matériau Bois Laboratoire d'Etudes et de Recherche sur le Matériau Bois Eberswalde University for Sustainable Development Laboratoire d'Etudes et de Recherche sur le Matériau Bois
• Publié dans European Journal of Wood and Wood Products le 26/10/2020

---

Résumé : Most European hardwoods are nowadays under-utilized due to drawbacks such as low dimensional stability, durability and surface hardness. Seven hardwood species were thermally and/or chemically modified in order to improve these disadvantages. Heat treatment was carried out in air at atmospheric pressure at three temperatures, while two types of chemical modifications were tested, the first being based on furfuryl alcohol with tartaric acid, the second being based on succinic anhydride and glycerol. Then, modified woods were studied to determine weight loss due to thermal treatment, solution uptake, weight percent gain and swelling due to chemical modification processes. After that, main properties of chemically modified woods were characterized including density, equilibrium moisture content, dimensional stability and surface hardness. Effect of thermal pretreatment on subsequent chemical modification and on properties of modified woods obtained have also been evaluated. Combination of thermal modification with chemical modification had led to better improvements than each separately. Furfurylation treatment appeared to be more efficient than polyester modification. Most of the modified samples were denser, more stable and harder than native wood. These modified woods might compete with imported tropical wood for applications requiring high stability and hardness, such as joinery, decking or flooring, music instruments, handles for tools or kitchen utensils.

---

Source

---

• Type de publi. :
• Date de publi. : 13/10/2023
• Auteurs : Philippe PierratPierre MagriJean-Jacques Gaumet
• Organismes : Laboratoire Lorrain de Chimie Moléculaire Laboratoire de Chimie et Physique - Approche Multi-échelle des Milieux Complexes Laboratoire de Chimie et Physique - Approche Multi-échelle des Milieux Complexes

---

Source

---

• Type de publi. : Chapître d'ouvrage
• Date de publi. : 13/10/2023
• Auteurs : Carine CalastrencFrançois BaleuxNicolas PoirierChristine RenduPierre CampmajoNicolas DobigeonNicolas MelladoClaire Marais-SicreMarie-Claude BalMagalie PhillippeMuriel Llubes
• Organismes : Travaux et recherches archéologiques sur les cultures, les espaces et les sociétés France, Amériques, Espagne, Sociétés, Pouvoirs, Acteurs Travaux et recherches archéologiques sur les cultures, les espaces et les sociétés Travaux et recherches archéologiques sur les cultures, les espaces et les sociétés France, Amériques, Espagne, Sociétés, Pouvoirs, Acteurs Travaux et recherches archéologiques sur les cultures, les espaces et les sociétés Signal et Communications Institut National Polytechnique (Toulouse) Centre National de la Recherche Scientifique Structural Models and Tools in Computer Graphics Centre d'études spatiales de la biosphère Géographie de l'environnement Géographie de l'environnement Géosciences Environnement Toulouse

---

Résumé : It took several decades of interaction and dialogue between human sciences and environmental sciences and a number of methodological advances for high altitude spaces to be considered as something other than immutable and atonic. Subjected to integrated interdisciplinary questioning, they reveal not one, but many complex histories and dynamics. By historicising mountain areas, the global point of view on societies is reversed and the whole of the valley systems are reconsidered. It is clear that the teams involved in this research are faced with the problem of acquiring primary information. An essential prerequisite for any archaeological research, high mountain prospecting has its own specificities and particular methodological challenges. How can we go beyond the threshold of the visible surface (micro-relief elevation) to enrich the information with infrastructures made of perishable materials or covered by vegetation? How can we systematise the acquisition to be able to process larger territories more quickly?Technological advances (photogrammetry, thermography, Lidar, georadar, magnetometer, chemical analysis of soils), the diversification and miniaturisation of sensors, the democratisation and development of aerial drones, which allow for the repeatability of acquisitions, are opening up the possibility of setting up new archaeological information acquisition procedures. The new data processing tools, the work on software ergonomics and the opening up of the field of possibilities offered by artificial intelligence allow us to foresee new possibilities for optimising the detection of archaeological remains in high altitude environments.

---

Fichiers liés : Article_Colloque_Nice_2022_Prog_TAHMM.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 13/10/2023
• Auteurs : Timothée BruelLou-Léna VrignaudFrançoise PorrotIsabelle StaropoliDelphine PlanasFlorence Guivel-BenhassineJulien PuechMatthieu ProtSandie MunierWilliam Henry BollandCathia SouliéKaren ZafilazaKaren ZafilazaClovis Lusivika-NzingaMarie-Laure MeledgeCéline DorivalDiana MolinoHélène PéréYouri YordanovEtienne Simon-LoriereDavid VeyerFabrice CarratOlivier SchwartzAnne-Geneviève MarcelinGuillaume Martin-BlondelMagalie GarciaValentin GiraudAgathe MetaisFance Cazenave-RoblotJean-Philippe Martellosio Anne-Marie RonchettiThomas GabasNaima HadjadjCélia SalanoubatAmélie ChabrolPierre HoussetAgathe PardonAnne-Laure FauconValérie CaudwellLatifa Hanafi Roland LiblauLaurent AlricGrégory PugnetMorgane MourguetEva BoriesDelphine BonnetSandrine CharpentierPierre DelobelAlexa DebardColleen BeckXavier BoumazaStella Rousset Fanny LanternierClaire DelageElisabete Gomes PiresMorgane CheminantNathalie Chavarot Anthony ChauvinXavier Eyer Véronique Delcey Simon BessisMélanie CrestaRomain Gueneau Pélagie ThibautMarine NadalMartin SiguierMarwa BachirChristia Palacios Valérie PourcherCléa MelenotteAntoine FaycalVincent BerotCécile BrinSiham DjebaraStéphane MarotSophie SayonVincent LeducqIsabelle MaletElisa TeyssouAdélie Gothland Karine LacombeYasmine Abi AadThibault ChiarabiniRaynald FelihoNadia ValinFabien BrigantJulien BoizePierre-Clément ThiébaudMarie MoreauCharlotte Billard Nathalie de CastroGeoffroy LiégeonBlandine DenisJean-Michel MolinaLucia Etheve André CabiéSylvie AbelOrnella CabrasKarine GuitteaudSandrine Pierre- François Vincent DubeeDiama NdiayeJonathan PehlivanMichael PhelippeauRafael Mahieu Alexandre DuvignaudThierry PistoneArnaud DesclauxDidier NeauCharles Cazanave Jean-François FaucherBenjamin FestouMagali Dupuy-GrassetVéronique Loustaud-RattiDelphine Chainier Nathan Peiffer- SmadjaChristophe ChoquetOlivia da ConceicaoMichael ThyLio CollasCindy GodardDonia BouzidVittiaroat IngLaurent PereiraThomas PavlowskyCamille Ravautantoine Asquier-KhatiDavid BoutoilleMarie ChauveauColin DeschanvresFrançois Raffi Audrey Le BotMarine CailleauxFrançois BenezitAnne MaillardBenoit HuePierre Tattevin François CoustilleresClaudia Carvalho-SchneiderSimon JamardLaeticia PetitKarl Stefic Natacha MrozekClément TheisMagali VidalLéo SauvatDelphine Martineau Benjamin LefèvreGuillaume BaronnetAgnès Didier Florence AderThomas PerpointAnne ConradPaul ChabertPierre Chauvelot Aurélie MartinPaul LoubetJulien MazetR. LarcherDidier Laureillard Mathilde Devaux Jérôme FreyAmos WoerlenAline RemillonLaure Absensur-VuillaumePauline Bouquet Albert Trinh-DucPatrick Rispal Philippe PetuaJulien Carillo Aurore PerrotKaren DelavignePierre CougoulJérémie DionOdile Rauzy Mathieu BlotThibault SixtFlorian MorettoCarole CharlesLionel Piroth Sophie CircostaLydia LegerArulvani ArulananthanCarine LascouxPascaline ValérieLeia Becam Yazdan YazdanpanahVentzislava Petrov-SanchezAlpha DialloSoizic Le MestreGuillaume Le Meut Isabelle GoderelFrédéric ChauBrahim SoltanaJessica Chane TangJérémie GuedjYvanie Caille
• Organismes : Virus et Immunité - Virus and immunity Vaccine Research Institute [Créteil, France] Virus et Immunité - Virus and immunity Vaccine Research Institute [Créteil, France] Sorbonne Université Virus et Immunité - Virus and immunity Virus et Immunité - Virus and immunity Virus et Immunité - Virus and immunity Vaccine Research Institute [Créteil, France] Virus et Immunité - Virus and immunity Hôpital Européen Georges Pompidou [APHP] Génomique évolutive des virus à ARN - Evolutionary genomics of RNA viruses Génomique évolutive des virus à ARN - Evolutionary genomics of RNA viruses Virus et Immunité - Virus and immunity École Doctorale Bio Sorbonne Paris Cité [Paris] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Pierre Louis d'Epidémiologie et de Santé Publique ANRS - Maladies infectieuses émergentes Hôpital Européen Georges Pompidou [APHP] Génomique fonctionnelle des tumeurs solides = Functional Genomics of Solid Tumors [CRC] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] Génomique évolutive des virus à ARN - Evolutionary genomics of RNA viruses Centre National de Référence des virus respiratoires (dont la grippe et le SARS-CoV2) [Paris] Génomique évolutive des virus à ARN - Evolutionary genomics of RNA viruses Hôpital Européen Georges Pompidou [APHP] Génomique fonctionnelle des tumeurs solides = Functional Genomics of Solid Tumors [CRC] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] Virus et Immunité - Virus and immunity Vaccine Research Institute [Créteil, France] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] Service Maladies infectieuses et tropicales [CHU Toulouse] Institut Toulousain des Maladies Infectieuses et Inflammatoires
• Publié dans Med le 16/06/2022

---

Résumé : Antibodies effective against the recent Omicron sublineages are missing. By taking advantage of a multi-centric prospective cohort of immunocompromised individuals treated for mild-to-moderate COVID-19, Bruel et al. show that administration of 500 mg of sotrovimab induces serum neutralization and antibody-dependent cellular cytotoxicity of BQ.1.1 and XBB.1.5. Therefore, sotrovimab may remain a therapeutic option against these variants.

---

Fichiers liés : 2023-07-17 ms letter HAL.pdf

---

Source

---

• Type de publi. :
• Date de publi. : 12/10/2023
• Auteurs : Philippe PierratPierre MagriJean-Jacques Gaumet
• Organismes : Laboratoire Lorrain de Chimie Moléculaire Laboratoire de Chimie et Physique - Approche Multi-échelle des Milieux Complexes Laboratoire de Chimie et Physique - Approche Multi-échelle des Milieux Complexes

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 11/10/2023
• Auteurs : Mikael CohenFabien RollotMarc DebouverieHélène ZéphirSandra VukusicJérôme de SèzePierre M LabaugeAurélie RuetÉric BergerDavid-Axel LaplaudJ CironBertrand BourreEmmanuelle Le PageCaroline PapeixEric ThouvenotAbdullatif Al KhedrBruno StankoffJean PelletierElisabeth MaillartOlivier CasezThibault MoreauGilles DeferPierre ClavelouPhilippe CabreSolène MoulinJean-Philippe NeauAbir WahabKarolina HankiewiczInès DoghriHaifa KhaledCorinne PottierLaurent MagyDalia Meshaka-Dimitri-BoulosDimitri BoulosOlivier HeinzlefJean-Philippe CamdessanchéMarc CoustansChantal NifleDavid BrassatRomain CaseyChristine Lebrun-Frénay
• Organismes : Centre Hospitalier Universitaire de Nice Université Claude Bernard Lyon 1 Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre Hospitalier Universitaire de Nancy Centre Hospitalier Régional Universitaire [CHU Lille] Université Claude Bernard Lyon 1 Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre Hospitalier Universitaire [Strasbourg] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Toulouse Institut Toulousain des Maladies Infectieuses et Inflammatoires CHU Rouen Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] CHU Amiens-Picardie Aix Marseille Université Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CHU Henri Mondor [Créteil] CHU Trousseau [Tours] CHU Limoges Université Claude Bernard Lyon 1 Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre Hospitalier Universitaire de Nice

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 11/10/2023
• Auteurs : Naïl BenallegueFabien RollotS WiertlewskiRomain CaseyMarc DebouverieEmmanuelle Le PageJérôme de SèzeJonathan CironAurélie RuetPierre M LabaugeElisabeth MaillartThi Helene ZephirCaroline PapeixGilles-Louis DeferChristine Lebrun-FrénayThibault MoreauEric BergerBruno StankoffPierre ClavelouOlivier HeinzlefJean PelletierEric ThouvenotAbdullatif Al KhedrBertrand BourreOlivier CasezPhilippe CabreAbir WahabLaurent MagyJean-Philippe CamdessanchéInès DoghriSolène MoulinHaifa KhaledKarolina HankiewiczJean-Philippe NeauCéline LabeyrieDalia Dimitri BoulosSandra VukusicDavid-Axel Laplaud
• Organismes : Centre Hospitalier Universitaire d'Angers Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation Eugène Devic EDMUS Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation Eugène Devic EDMUS Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Service de neurologie [CHRU Nancy] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre d'Investigation Clinique [Rennes] CIC Strasbourg Service de Neurologie [Strasbourg] Institut Toulousain des Maladies Infectieuses et Inflammatoires Département Neurologie [CHU Toulouse] Centre d'investigation clinique de Toulouse Centre Hospitalier Universitaire de Bordeaux Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale Département de Neurologie [Hôpital Gui de Chauliac - CHU Montpellier] CHU Pitié-Salpêtrière [AP-HP] Hôpital Roger Salengro [Lille] Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Lille] Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Service de Neurologie [CHU Caen] Centre de Ressources et de Compétences sur la Sclérose en Plaques (CRC-SEP) [Caen] Service de Neurologie [CHU Nice] Unité de Recherche Clinique Côte d’Azur Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) Service de Neurologie [CHRU Besançon] CHU Saint-Antoine [AP-HP] Service Neurologie [CHU Clermont-Ferrand] Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM] Institut de Génomique Fonctionnelle Service de Neurologie [CHU Nimes] Service de neurologie [Amiens] CHU Rouen Centre Hospitalier Universitaire [CHU Grenoble] Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Hôpital Henri Mondor Service de Neurologie [CHU Limoges] Service de Neurologie [CHU de Saint-Étienne] CHU Trousseau [Tours] Service de neurologie [Reims] Centre Hospitalier Sud Francilien Centre Hospitalier de Saint-Denis [Ile-de-France] Service de neurologie [CHU de Poitiers] Service de neurologie [Le Kremlin Bicêtre] Service de neurologie [Le Kremlin Bicêtre] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation Eugène Devic EDMUS Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital

---

Résumé : Introduction: Moderately-effective therapies (MET) have been the main treatment in pediatric- onset multiple sclerosis (POMS) for years. Despite the expanding use of highly-effective therapies (HET), therapeutic guidelines for POMS are missing. Objectives/Aims: To assess the real-world effectiveness of HET as immediate treatment compared with MET on disease activity. Methods: In this retrospective observational study, we used datafrom 36 French MS expert centers participating in the Observatoire Français de la Sclérose en plaques (OFSEP), the French MS registry. We included treatment-naïve children (aged under 18 years) with relapsing-remitting MS who initiated HET or MET from 2010 to 2022. We used an innovative statistical method to model the logarithm of event rates by a penalized splines of time, allowing the possibility to model the effects of covariates in a flexible way considering non-linearity and interactions. Results: A total of 530 children were identified and met inclusion criteria (422 MET and 108 HET). Both HET and MET treatment strategies reduced the risk of first relapse within the first 2 years. HET dampened the occurrence of a first relapse with a 54% risk reduction compared to MET (adjusted Hazard Ratio HR 0.46 [95% CI 0.31-0.67]; p<0.001) and a sustained effect over 5 years of follow-up, confirmed on MRI activity (adjusted OR 0.34 [95% CI 0.18-0.66]; p=0.001) and with a better tolerability pattern. MET had six times more risk of discontinuation at 2 years (HR 5.97 [95% CI 2.92-12.20]). Index treatment was not associated with enrollment in tertiary education. Conclusion: HET as first-line strategy in POMS reduces the occurrence of a first-relapse with an optimal effect within the two first-years compared to treatment escalation, supporting a need to use immediate HET in POMS.

---

Source